Literature DB >> 7740519

Hemostasis activation in patients with liver cirrhosis.

T Vukovich1, H Teufelsbauer, M Fritzer, S Kreuzer, P Knoflach.   

Abstract

In patients with liver cirrhosis a decrease of the coagulant potential is well-documented and has been linked to the high bleeding tendency among these patients. Whether the decrease of the coagulant potential is only due to a reduced hepatic synthesis of coagulation factors or also to its consumption by disseminated intravascular coagulation is debatable. We investigated hemostasis activation markers thrombin-antithrombin III complexes (TAT), fibrin degradation products (D-Dimer) and plasmin-alpha 2-antiplasmin complexes (PAP) in 41 outpatients with liver cirrhosis (Child-Pugh index 1 n = 18, 2 n = 15, 3 n = 8). Compared to controls similar in terms of age and sex, TAT, D-Dimer and PAP was elevated in the whole group of patients. A progressive increase of D-Dimer and PAP from Child 1 to 3 indicates a relationship between the severity of cirrhosis and the amount of hemostasis activation. Investigation of the natural anticoagulant potential showed significant decreases of antithrombin III (AT III), protein C, and protein S, most pronounced in Child 3 patients. Statistical analysis revealed significant negative correlations between levels of D-Dimer and both AT III and protein C, indicating that hemostasis activation is linked to the loss of anticoagulant potential.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7740519     DOI: 10.1016/0049-3848(95)91614-q

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  D-dimer for the diagnosis of acute venous thromboembolism in the emergency department: a Janus-face marker.

Authors:  Roberto Manfredini
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

2.  Assessing in vivo platelet activation in patients with liver diseases.

Authors:  Ton Lisman
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

3.  Abnormalities in liver function and coagulation profile following the Fontan procedure.

Authors:  R C van Nieuwenhuizen; M Peters; L J Lubbers; M D Trip; J G Tijssen; B J Mulder
Journal:  Heart       Date:  1999-07       Impact factor: 5.994

4.  Spontaneous bleeding or thrombosis in cirrhosis: What should be feared the most?

Authors:  Kryssia Isabel Rodríguez-Castro; Alessandro Antonello; Alberto Ferrarese
Journal:  World J Hepatol       Date:  2015-07-18

5.  Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis?

Authors:  Valeria Rossetto; Luca Spiezia; Marco Senzolo; Krissia Isabel Rodriguez-Castro; Sabrina Gavasso; Barry Woodhams; Paolo Simioni
Journal:  Intern Emerg Med       Date:  2013-03-17       Impact factor: 3.397

6.  The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study.

Authors:  Ellen G Driever; Marta Magaz; Jelle Adelmeijer; Fanny Turon; Anna Baiges; Pol Olivas; Valeria Pérez-Campuzano; Virginia Hernandez-Gea; Annabel Blasi; Juan-Carlos Garcia-Pagan; Ton Lisman
Journal:  J Thromb Haemost       Date:  2022-07-11       Impact factor: 16.036

Review 7.  Perioperative thromboprophylaxis in liver transplant patients.

Authors:  Lesley De Pietri; Roberto Montalti; Daniele Nicolini; Roberto Ivan Troisi; Federico Moccheggiani; Marco Vivarelli
Journal:  World J Gastroenterol       Date:  2018-07-21       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.